Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.

Publication Type:

Journal Article

Source:

Journal of gastrointestinal cancer, Volume 43, Issue 2, p.215-23 (2012)

Keywords:

Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Cisplatin, Clinical Trials, Phase III as Topic, Cost-Benefit Analysis, Decision Support Techniques, Deoxycytidine, Disease-Free Survival, Humans, Quality-Adjusted Life Years, Randomized Controlled Trials as Topic

Abstract:

The ABC-02 trial demonstrated a statistically significant survival benefit associated with the addition of cisplatin to gemcitabine in the palliative treatment of advanced biliary tract cancer (BTC). Based on the ABC-02 findings, this analysis seeks to evaluate the cost-utility of adding cisplatin to standard gemcitabine therapy from a U.S. societal perspective.